QAIALDO

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania

Active ingredients

The drug QAIALDO contains one active pharmaceutical ingredient (API):

1 Spironolactone UNII 27O7W4T232 - SPIRONOLACTONE

Spironolactone, as a competitive aldosterone antagonist, increases sodium excretion whilst reducing potassium loss at the distal renal tubule. It has a gradual and prolonged action. Read about Spironolactone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
QAIALDO Oral suspension	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C03DA01	Spironolactone	C Cardiovascular system → C03 Diuretics → C03D Potassium-sparing agents → C03DA Aldosterone antagonists
Discover more medicines within C03DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3036844
Country: IT	Agenzia del Farmaco	Identifier(s): 050700018
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097210